Who is a good candidate for this injection

For many patients over 60, the first question is whether advanced hip wear or age itself rules out treatment. With ChondroFiller injection, neither does.

The injection carries no upper age limit and no defect-size ceiling. It is specifically designed for diffuse, advanced joint wear — including Kellgren-Lawrence Grade III and IV osteoarthritis, the degree of narrowing and damage that a scan typically shows in patients in their 60s, 70s and beyond. Focal isolated defects and more widespread degenerative changes are both within scope.

Positive indicators

• Cartilage wear visible on MRI, whether in one area or across the joint surface
• Degenerative or post-traumatic chondral damage
• Stable joint mechanics — no major structural imbalance in the hip
• An active lifestyle and a preference to preserve the natural joint before considering replacement

When other issues need addressing first

ChondroFiller injection is most effective in a mechanically stable hip. Untreated ligament instability, significant joint malalignment, or an active soft-tissue problem driving accelerated wear should be assessed and managed before proceeding — not because they disqualify a patient permanently, but because treating the underlying cause first gives the scaffold the best environment to work in.

For active patients in their 60s and 70s who are not yet ready for hip replacement, this injection pathway is designed with them squarely in mind. A consultant assessment and current MRI remain the starting point to confirm individual suitability.

Why reduced regenerative capacity does not disqualify older adults

Regenerative procedures that depend on the body producing large volumes of new tissue — some surgical cartilage repair techniques included — perform best in a biologically active, high-regeneration environment. That is precisely why age can be a limiting factor for those pathways. ChondroFiller injection works differently.

The injectable collagen scaffold operates through acellular matrix-induced chondrogenesis: once placed in the joint under ultrasound guidance, the scaffold recruits the patient's own progenitor cells from the surrounding synovium and subchondral bone, which gradually populate and remodel the matrix. Critically, the scaffold also acts as a biological cushion layered over worn joint surfaces — a protective, additive role it performs even where significant new tissue formation does not occur. Effectiveness is not contingent on generating large volumes of replacement cartilage, which is why reduced regenerative capacity, typical in the older joint, is not a disqualifying factor here.

This is a deliberate clinical distinction from the surgical Liquid Cartilage™ keyhole pathway, which does depend on host regenerative potential and is assessed individually on that basis. The injectable route was designed, in part, to extend a biological option to patients for whom a growth-dependent repair would be unsuitable.

Femoroacetabular impingement (FAI) is also within the clinical remit of this injection. FAI — a structural mismatch between the ball and socket of the hip — frequently underlies cartilage wear in middle-to-older adult patients and is covered by the published hip evidence base, including the Perez-Carro et al. 2021 study reporting +33 Harris Hip Score improvement.

What the appointment involves

No theatre booking, no general anaesthetic, no overnight stay — for older adults weighing up the risks of any procedure, these are the most relevant facts about a ChondroFiller injection appointment.

The session takes approximately 30 to 45 minutes and is conducted in an outpatient clinic setting. Under real-time ultrasound guidance, the injectable collagen scaffold is placed precisely into the hip joint without a surgical incision or the need for recovery-ward monitoring. A single appointment covers initial consultation, diagnostic ultrasound, product placement, and intravenous antibiotic cover; a six-week follow-up is arranged before the patient leaves.

The absence of general anaesthesia carries particular weight for this patient group. Patients in their 60s, 70s and beyond often carry elevated anaesthetic risk — cardiac, respiratory, or renal comorbidities that make even routine surgery a more considered decision. An ultrasound-guided injection bypasses that risk category entirely.

At the London Cartilage Clinic on Harley Street, the treatment is delivered by Professor Paul Y. F. Lee, the UK's certified clinician for the Liquid Cartilage™ pathway. Patients leave the same day. The procedure does not require an operating theatre, and there is no surgical debridement of the joint.

Recovery timeline and what the evidence shows for the hip

Improvement after a ChondroFiller injection is not immediate — understanding the timeline prevents both premature disappointment and premature reassurance.

Structural benefit builds progressively over six to twelve months as the patient's own progenitor cells migrate into the collagen scaffold and begin remodelling it into cartilage-like matrix. The joint does not feel markedly different on the drive home. Most patients report gradual easing of pain and improved range of movement across the first several months, with the clearest gains visible by the six-month mark.

What the hip evidence actually shows

The principal published hip study — Perez-Carro et al. 2021 — reported a Harris Hip Score improvement of approximately +33 points in the studied patient group. For patients unfamiliar with that scale: a gain of that magnitude typically translates to significantly reduced resting and walking pain, improved ability to manage stairs, and a meaningful extension of comfortable walking distance. Harris Hip Score measures exactly the functional domains that matter most to someone whose hip wear has begun limiting daily life. That said, Perez-Carro et al. represents a single published series; outcomes vary according to defect severity, individual biology, and stage of disease, and the figure should be treated as a clinical reference point rather than a guaranteed result.

MRI findings corroborate the functional data. Post-treatment imaging consistently shows reduction in bone marrow oedema, diminished periarticular effusion, and visible widening of joint space — structural markers that reflect genuine change in the joint environment rather than symptom masking alone. Across joint applications, MOCART MRI regeneration scores of 70 to 87 have been reported, and sustained outcomes have been documented at five years and beyond in suitable patients.

Rehabilitation and recovery load

There is no non-weight-bearing phase after a ChondroFiller injection, and no physiotherapy-intensive post-operative programme of the kind that follows surgical cartilage repair. Patients typically resume light activity the same day and return to normal walking within a day or two. The rehabilitation burden is substantially lower than any surgical comparator — a meaningful consideration for older adults who may have limited support at home or reduced tolerance for extended recovery periods.

When more than one injection may be needed

Single-agent ChondroFiller injection addresses the scaffold and regeneration side of hip cartilage wear — but for patients with Kellgren-Lawrence Grade III or IV osteoarthritis where the joint environment is more complex, additional agents targeting different tissue compartments may be considered alongside it.

The most established combination is Dual Active Therapy: ChondroFiller injection applied to the bone surfaces as the regenerative scaffold component, paired with Arthrosamid, a polyacrylamide hydrogel injected into the synovial compartment. These two products should not be treated as variations of the same intervention. Arthrosamid is a permanent hydrogel that cushions the synovium; it is not a regenerative scaffold and does not recruit the patient's cells to build new matrix. The combination works because the two agents address different roles in the joint rather than duplicating one another. Guide cost for this dual approach is approximately £6,000, self-funded.

For more advanced presentations, a Tri-Active option adds autologous mesenchymal stem cells to the ChondroFiller and Arthrosamid combination, at a guide cost of approximately £11,000 self-funded. A related three-way protocol — sometimes referred to as NanoACi, combining ChondroFiller with MSCs and platelet-rich fibrin — is available as an emerging option, but has not yet been validated as a combined protocol in randomised trials; it should be understood as an area of active clinical development rather than an established evidence pathway.

For older adults managing a progressive condition over years rather than months, a Longitudinal Lifetime Program offers yearly MRI monitoring alongside bi-annual ChondroFiller top-up injections — a structured approach to joint preservation aimed at delaying or avoiding total hip replacement. Suitability for any combination approach is determined at consultation.

Getting assessed at the London Cartilage Clinic

Liquid Cartilage™ is available in the UK through the London Cartilage Clinic on Harley Street — the certified UK delivery centre for ChondroFiller injection. Treatment is self-funded private; no NHS or standard private medical insurance coverage is currently available, and patients should expect to confirm costs directly with the clinic before booking.

An assessment begins with a review of any existing MRI or X-ray imaging — or new imaging can be arranged if needed — followed by a clinical discussion of candidacy and, where appropriate, a personalised treatment plan. The conversation is diagnostic rather than prescriptive: some patients will be suitable for single-agent ChondroFiller injection; others may be better served by one of the combination approaches discussed above; and a proportion will be better directed elsewhere.

Patients from London and the wider commuter belt can book an assessment at londoncartilage.com.